Elsevier

Clinica Chimica Acta

Volume 223, Issues 1–2, 31 December 1993, Pages 43-52
Clinica Chimica Acta

Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy

https://doi.org/10.1016/0009-8981(93)90061-8Get rights and content

Abstract

The effect of tamoxifen on serum cholesterol, high density lipoprotein cholesterol (HDL- low density lipoprotein cholesterol (LDL-cholesterol) and the ratio of LDL-cholesterol to HDL-cholesterol (LDL-C/HDL-C) was investigated in breast cancer patients undergoing therapy for advanced disease. Longitudinal studies in 24 patients treated with tamoxifen (10 mg, twice daily) indicated average decreases in total serum cholesterol (17%) and LDL-cholesterol (27%), whereas the effect of tamoxifen on HDL-cholesterol varied with the individual patient. There was a significant decrease in the LDL-C/HDL-C ratio (33%) consistent with a decreased risk for coronary artery disease. This beneficial influence of tamoxifen on risk factors associated with cardiovascular disease was evident in both premenopausal and postmenopausal patients whether tamoxifen was administered alone or in combination with cytotoxic chemotherapy.

References (33)

  • T Gordon et al.

    High density lipoprotein as a protective factor against coronary artery disease: the Framingham study

    Am J Med

    (1977)
  • VC Jordan

    Chemosuppression of breast cancer with tamoxifen: laboratory evidence and 3 future clinical investigations

    Cancer Invest

    (1988)
  • VC Jordan

    Long-term adjuvant tamoxifen therapy for breast cancer

    Breast Cancer Res Treat

    (1990)
  • VC Jordan

    Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention

    Cancer Treat Rev

    (1990)
  • VC Jordan

    The strategic use of antiestrogens to control the development and growth of breast cancer

    Cancer

    (1992)
  • VC Jordan et al.

    Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study

    J Clin Oncol

    (1990)
  • B Fisher

    Evaluation of paradigms for the management of breast cancer: a personal perspective

    Cancer Res

    (1992)
  • S Rousser et al.

    Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen

    Atherosclerosis

    (1984)
  • G Bertelli et al.

    Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

    Breast Cancer Res Treat

    (1988)
  • PF Bruning et al.

    Serum lipoproteins and cardiovascular risk

    Br J Cancer

    (1988)
  • TJ Powles et al.

    A pilot trials to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

    Br J Cancer

    (1989)
  • JD Bagdade et al.

    Effect of tamoxifen treatment on plasma lipids and lipoprotein lipid composition

    J Clin Endocrinol Metab

    (1990)
  • D Ingram

    Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer

    Aust NZ J Surgery

    (1990)
  • DV Shapira et al.

    Serum cholesterol reduction with tamoxifen

    Breast Cancer Res Treat

    (1990)
  • RR Love et al.

    Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

    Ann Intern Med

    (1991)
  • RR Love et al.

    Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer

    J Natl Cancer Inst

    (1990)
  • Cited by (46)

    • Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR

      2021, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Furthermore, we and others have shown that SERMs reduce cholesterol biosynthesis by inhibiting the activity of post-lanosterol enzymes [13,15,16]. These effects may account for the low levels of circulating cholesterol described in patients taking these drugs [15,17–19]. We have also found that SERMs block the egress of LDL-derived cholesterol from lysosomes, thus explaining the synergistic effect with LOV on LDLR expression in cell lines [13,14].

    • Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice

      2015, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Furthermore, Tam treated animals showed increased serum levels of triglycerides and free fatty acids compared to control animals. Serum HDL, LDL and total cholesterol levels were comparable between the two groups, in spite of what was shown by previous investigations [13,14]. Higher levels of serum triglycerides and free fatty acids might be a direct consequence of the conversion from white to beige adipocytes, because as known from literature lipid droplets of brown and beige adipocytes are smaller and scattered throughout.

    • Women, dyslipoproteinemia, and estrogens

      1998, Endocrinology and Metabolism Clinics of North America
    View all citing articles on Scopus
    View full text